BPGbio Announces Publication in Scientific Reports on Validation of Novel Diagnostic Biomarker Panel for Parkinson’s Disease
20 Mayo 2024 - 6:00AM
Business Wire
- The findings highlight the success of BPGbio’s NAi
Interrogative Biology Platform in identifying a biomarker for
disease diagnosis
- Easy blood test significantly enhances risk assessment for
Parkinson’s Disease diagnosis
BPGbio, a leading biology-first AI-powered biopharma that
focuses on oncology, neurology, and rare diseases, announced today
the publication of a significant, multi-year research effort titled
“Identification and validation of N-acetylputrescine in combination
with non-canonical clinical features as a Parkinson’s disease
biomarker panel” in Scientific Reports.
Parkinsons Disease (PD) is a progressive neurological disease,
which occurs when brain cells in a particular brain region that
make dopamine, a chemical that coordinates movement, stop
functioning or die. By the time motor symptoms appear, 60-80% of
dopamine cells are already lost. PD is difficult to diagnose and
often relies upon clinical judgment, sometimes aided by imaging,
after the clinician has ruled out other potential causes of patient
symptoms. According to the Michael J. Fox Foundation, PD affects
nearly 6 million people worldwide and nearly 1 million people in
the United States. Early identification and treatment would improve
long term outcomes for patients.
BPGbio researchers built their systems biology model using
patient samples from nearly 400 individuals collected in a
prospective clinical trial by renowned Parkinson’s disease
researchers Drs. William Langston and Birgitt Scheule at the
Parkinson’s Institute. Using BPGbio’s NAi Interrogative Biology
platform, the BPGbio team identified and developed a CLIA-validated
test for measurement of N-acetylputrescine, a novel biomarker for
PD, and studied its use in combination with specific clinical
features – sense of smell, depression and nightmare – as a
predictor of PD. The paper details how the assessed diagnostic
panel using patients’ plasma in combination with these specific
clinical features significantly enhances the accuracy of PD
diagnosis and improves risk assessment for PD, thus validating the
utility of this new biomarker.
"Our findings offer a promising new avenue for early and more
accurate risk assessment of PD by helping clinicians understand
patients’ trajectory toward PD to enable intervention in earlier
stages of the disease,” stated Michael A. Kiebish, Ph.D., lead
investigator of the research and VP of Platform and Translational
Sciences at BPGbio. “Additionally, a simple blood draw is a big
step towards improving PD diagnosis and making screening easier for
clinicians and their patients.”
Eric J. Nestler, M.D., Ph.D., Nash Family Professor of
Neuroscience at the Icahn School of Medicine at Mount Sinai in New
York and scientific advisory board member of BPGbio added, “PD is a
very common condition and only about 10% of cases are highly
genetic. There are currently no effective tools available today to
diagnose PD before motor symptoms appear. This novel biomarker
panel from BPGbio offers the potential to address this unmet
need.”
BPGbio has trademarked its parkinsonDx panel and is exploring
partnerships to commercialize this innovative product.
About BPGbio, Inc.
BPGbio is a leading AI-powered clinical stage biopharma and
diagnostics company focused on oncology, neurology, and rare
diseases. The company has a deep portfolio of AI-developed pipeline
of therapeutics, including several in late-stage development.
BPGbio’s novel approach is underpinned by NAi, its proprietary
Interrogative Biology Platform, protected by over 400 US and
international patents; one of the world’s largest clinically
annotated non-governmental biobanks; and exclusive access to the
most powerful supercomputer in the world. With these tools, BPGbio
is redefining how patient biology can be modeled using unbiased AI.
Headquartered in Boston, the company is at the forefront of a new
era in medicine, combining biology, data, and AI to transform the
way we understand aging, human performance, and diagnose and treat
disease. For more information, visit bpgbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240520092134/en/
media@bpgbio.com